Fundraising Fox
/Companies
Sign in

Biohaven Pharmaceuticals

6 known investors

Find your way into Biohaven Pharmaceuticals

Sign up to see every warm intro you have to Biohaven Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Biohaven Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options. Its commercialized products include migraine therapies, and it advances a portfolio of early- to late-stage drug development programs.

BiotechHealthtech

Founders & leadership

VCVlad Coric
Vlad CoricChairman & Chief Executive OfficerVlad Coric is Chairman and Chief Executive Officer of Biohaven Pharmaceuticals, a biopharmaceutical company developing treatments in neuroscience, immunology, metabolic disorders, rare disease, and oncology. He has over 25 years of clinical and research experience and previously led development of Nurtec ODT, a migraine treatment that was acquired by Pfizer.

Investors · 6

APERTURE Venture Partnerslisted by APERTURE Venture PartnersNew York · $1M – $5M

How we know: APERTURE Venture Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Connecticut Innovationslisted by Connecticut InnovationsNew Haven · $500K – $2M

How we know: Connecticut Innovations's portfolio page · Not right? Tell us

OUP (Osage University Partners)listed by OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us

HBM Healthcare InvestmentsreportedZug

How we know: press coverage · Not right? Tell us

OrbiMedreportedNew York · $1M – $75M

How we know: press coverage · Not right? Tell us

In the news

BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Regionprnewswire.com · Sep 2020

Frequently asked questions

What does Biohaven Pharmaceuticals do?
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options. Its commercialized products include migraine therapies, and it advances a portfolio of early- to late-stage drug development programs.
Who are Biohaven Pharmaceuticals's investors?
Biohaven Pharmaceuticals's investors include Aisling Capital, APERTURE Venture Partners, Connecticut Innovations, OUP (Osage University Partners), HBM Healthcare Investments, OrbiMed.